MercadoLibre (NASDAQ:MELI) opened 2026 with what executives repeatedly characterized as an investment-led quarter, highlighting accelerating growth in both commerce and fintech while acknowledging margin pressure tied to a deliberate push to scale key initiatives. During the company’s earnings call
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Microchip Technology (NASDAQ:MCHP) reported March-quarter results that exceeded its prior guidance and pointed to continued momentum heading into the June quarter, as management said demand is improving across end markets and distributor inventory appears to have normalized. Quarterly and full-year
Lyft (NASDAQ:LYFT) executives used the company’s first-quarter 2026 earnings call to highlight what CEO David Risher described as “another strong quarter,” pointing to double-digit year-over-year gains in active riders, gross bookings and adjusted EBITDA. Risher said rideshare demand “remained healt
Lexicon Pharmaceuticals (NASDAQ:LXRX) executives highlighted progress across late-stage regulatory programs and efforts to bolster the company’s financial position during the company’s first-quarter 2026 earnings call on May 7. Chief Executive Officer Mike Exton said the company entered 2026 with o
PAYC tops Q1 estimates as revenues climb 7.8% Y/Y, margins expand, and the company reaffirms its 2026 outlook.
Super Micro Computer gave investors the kind of earnings report that usually fits neatly into the artificial-intelligence growth story, with revenue more than doubling from the prior year and management pointing to stronger demand ahead. Super Micro shares recently traded at $34.66, up 24.50% from ...
LightPath Technologies (NASDAQ:LPTH) reported fiscal third-quarter 2026 results on May 7, highlighting what management described as continued momentum in revenue growth, backlog expansion, and improving profitability as the company executes a multi-year shift from components to vertically integrated
Q1 earnings trigger fresh questions for Trade Desk (TTD) Trade Desk (TTD) reported first quarter 2026 results with sales of US$688.86 million and net income of US$40 million, while issuing guidance below market expectations for the next quarter. The mix of revenue growth, lower earnings per share versus a year earlier and softer forward guidance, together with new partnerships and data oversight scrutiny, gives investors several factors to consider with this stock. See our latest analysis for...
Eaton Corporation plc recently reported past first-quarter 2026 results, with sales rising to US$7,451 million from US$6,377 million a year earlier, while net income eased to US$866 million and diluted EPS from continuing operations slipped to US$2.22 from US$2.45. Alongside closing about US$11.00 billion of acquisitions and highlighting surging AI data center demand, Eaton raised its 2026 organic growth and adjusted EPS guidance, underlining management’s confidence in its power management...
nLight (NASDAQ:LASR) reported what management called an “exceptional” first quarter of 2026, with revenue, margins, and profitability coming in ahead of internal expectations as aerospace and defense demand remained the primary growth driver. Chairman and CEO Scott Keeney said Q1 results “comfortab
Kodiak AI (NASDAQ:KDK) executives used the company’s first-quarter fiscal 2026 earnings call to highlight a $100 million capital raise, progress scaling paid driverless operations, and new partnerships spanning long-haul trucking, industrial applications, and defense. Founder and CEO Don Burnette s
IREN (NASDAQ:IREN) used its fiscal third-quarter earnings call to highlight a rapid expansion in AI data center capacity, a new long-term customer agreement with NVIDIA, and continued progress in shifting its business mix away from Bitcoin mining and toward AI Cloud services. Strategic focus: conve
Iovance Biotherapeutics (NASDAQ:IOVA) reported first-quarter 2026 revenue of $71 million, up roughly 45% year-over-year, as the company pointed to rising demand for its tumor-infiltrating lymphocyte (TIL) therapy AMTAGVI and expanding commercial execution. Management also reiterated that recent manu
Inspired Entertainment (NASDAQ:INSE) executives said first-quarter results reflected the benefits of portfolio changes made in 2025, highlighting strong Interactive growth, margin expansion, and improved cash generation that supported both debt reduction and share repurchases. Executive Chairman A.
Inseego (NASDAQ:INSG) reported first-quarter fiscal 2026 results that management said were in line with expectations, while also outlining the strategic rationale and structure for its planned acquisition of Nokia’s fixed wireless access (FWA) device business. Q1 revenue rose 8% year over year as s
Innodata (NASDAQ:INOD) reported what management described as a “record-setting” first quarter of 2026, posting new highs in revenue, adjusted gross profit, adjusted EBITDA, and cash while raising its full-year growth outlook. Executives also detailed new and expanding engagements across large techno
Shares in Sunnyvale, Calif.-based company rose an eye-popping 20% Thursday, a day after executives reported an earnings beat.
indie Semiconductor (NASDAQ:INDI) reported first-quarter 2026 revenue of $55.5 million, topping the midpoint of its prior outlook by about $0.5 million and increasing roughly 3% year-over-year, as the automotive chip supplier cited improving market conditions and continued demand for higher semicond
Himax Technologies (NASDAQ:HIMX) reported first-quarter 2026 results that came in above its prior profit outlook despite a typical seasonal slowdown around the Lunar New Year period, as management pointed to improving demand trends into the second quarter alongside continued cost pressures tied to t
AMD just posted its strongest quarter as an AI company. The stock surged nearly 18% on the day. And one analyst responded by nearly doubling his price target. The move from Bernstein is not a routine post-earnings trim. It is a fundamental reassessment of what AMD is worth and where it is heading. ...
McDonald’s Corporation will release earnings for its first quarter before the opening bell on Thursday, May 7. Analysts expect the company to report quarterly earnings of $2.74 per share, up from $2.67 per share in the year-ago period. The consensus...
Ziff Davis (ZD) delivered earnings and revenue surprises of +1.39% and -0.88%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Ready Capital (RC) delivered earnings and revenue surprises of -153.85% and -217.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Howard Hughes Holdings (HHH) delivered earnings and revenue surprises of +75.00% and +9.67%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Ivanhoe Electric (IE) delivered earnings and revenue surprises of -73.33% and -4.67%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
AvePoint (AVPT) delivered earnings and revenue surprises of +30.38% and +0.89%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Century (CENX) delivered earnings and revenue surprises of -8.62% and -0.46%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
ABSCI CORP (ABSI) delivered earnings and revenue surprises of +5.00% and -90.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Applied Optoelectronics (AAOI) delivered earnings and revenue surprises of -31.33% and -3.40%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Gilead Sciences (NASDAQ:GILD) reported first-quarter 2026 results highlighted by growth in its base business, a higher full-year revenue outlook, and multiple late-stage pipeline and launch milestones across HIV, oncology, liver disease, and inflammation. Executives repeatedly pointed to “consistent